Astellas Pharma Enzalutamide (#XTANDI) granted European Commission approval for use in additional recurrent early #ProstateCancer treatment setting. Approval based on results of the #EMBARK study. #ReadNow details on UroToday > https://bit.ly/3Wi0RQC
About us
Welcome to Digital Science Press, Inc. the publisher of UroToday + GU OncToday and Everyday Urology - Oncology Insights largest global online community of urological medical professionals, pharmaceutical and medical device companies, and the patients they serve. UroToday delivers credible, timely and accurate urological disease and treatment information to more than 86,000 Urologists, GU Oncologists, healthcare providers, industry and patients from 206 counties around the globe. Through our learning network, urological healthcare professionals share their clinical experience, learn from each other and improve patient outcomes. Our mission is to foster a global platform of shared collegial experience and learning that will help shape the delivery of urological care around the world. On UroToday, more than 850 faculty from global medical institutions share their expertise in urological treatment from publications, clinical practice and new surgical technologies with colleagues they know and trust. They also gain insights that impact conversations with patients and each other, leading to improved patient care and treatment outcomes. UroToday produces and shares independent urological content. Our sponsors include medical device makers and pharmaceutical companies, along with consumer product manufacturers who want to reach urological health professionals.
- Website
-
http://www.urotoday.com
External link for Digital Science Press
- Industry
- Book and Periodical Publishing
- Company size
- 2-10 employees
- Headquarters
- San Francisco, California
- Type
- Privately Held
- Founded
- 2003
- Specialties
- Medical information urology and GU oncology, Urological surgical procedures & instrumentation, Interactive content on urological disease information, and Deliver editorial content free of commercial influence
Locations
-
Primary
548 Market St
San Francisco, California 94104, US
Employees at Digital Science Press
Updates
-
Ferring Pharmaceuticals adds three new studies to non-muscle invasive #BladderCancer clinical trial program with nadofaragene firadenovec-vncg (ADSTILADRIN®). #ReadNow details on UroToday > https://bit.ly/3W5sb4q
-
Blue Earth Therapeutics announces promising results from preclinical evaluation of synergistic drug combinations with radiopharmaceutical 177Lu-rhPSMA-10.1 for the treatment of #ProstateCancer. #ReadNow details on UroToday > https://bit.ly/3U877J6 American Association for Cancer Research
-
Novartis confirms plans to file for Pluvicto® Pre-Taxane Label Expansion in H2 2024 based on the latest data from phase III #PSMAfore study. #ReadNow for details > https://bit.ly/3xpXFI2
-
Photocure announces study on racial differences in the detection rate of #BladderCancer using Blue Light Cystoscopy published in #Cancers. #ReadNow details on UroToday > https://bit.ly/3xeCskt
-
#SECuRE Update: Clarity Pharmaceuticals announces the first participant treated in the last cohort of dose escalation. #ReadNow details on UroToday > https://bit.ly/3TPKw3D #ProstateCancer
-
Save the date! April 6th, 2024, Moffitt Cancer Center is hosting the #ProstateCancer Patient Symposium. Raising awareness about the latest treatments and resources available, addressing health disparities, and encouraging community involvement. More info > https://fb.me/e/4ehdN7Hyf
-
Exciting news in #WomensHealth! Cosm Medical receives FDA clearance for Gynethotics™ Pessaries, marking a breakthrough in personalized pelvic care. This innovative solution aims to revolutionize treatment options for millions of women worldwide. #ReadNow details on UroToday > https://bit.ly/4ahFeDx
-
Photocure partner Asieris Pharmaceuticals announces positive international phase III clinical trial results for cevira and data presentations at the 2024 #EUROGIN Congress and SGO Annual Meeting. #ReadNow details on UroToday > https://bit.ly/3IHXvOM Society of Gynecologic Oncology EUROGIN Conference
-
Exciting news in the fight against metastatic castrate-resistant #ProstateCancer! Clarity Pharmaceuticals advances to multi-dose phase in #SECuRE trial with promising results. #Readnow details on UroToday > https://bit.ly/48YPBv8 #PressRelease